Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
63.6M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
62.3M
-
Shares change
-
+2.85M
-
Total reported value, excl. options
-
$1.81B
-
Value change
-
+$85.3M
-
Put/Call ratio
-
0.79
-
Number of buys
-
66
-
Number of sells
-
-34
-
Price
-
$29.12
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q4 2022
136 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q4 2022.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.3M shares
of 63.6M outstanding shares and own 97.98% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (6.91M shares), BAKER BROS. ADVISORS LP (6.35M shares), FEDERATED HERMES, INC. (6.3M shares), RA CAPITAL MANAGEMENT, L.P. (5.52M shares), GOLDMAN SACHS GROUP INC (5.2M shares), NEA Management Company, LLC (4.91M shares), BlackRock Inc. (3.72M shares), STATE STREET CORP (3.18M shares), VANGUARD GROUP INC (2.6M shares), and ALKEON CAPITAL MANAGEMENT LLC (2.24M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.